Shanghai Henlius Biotech Receives Regulatory Approval to Begin Phase 1b/2 Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours in China

Reuters
09/30
<a href="https://laohu8.com/S/SGBCF">Shanghai Henlius Biotech</a> Receives Regulatory Approval to Begin Phase 1b/2 Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours in China

**Shanghai Henlius Biotech Receives Regulatory Approval for New Cancer Clinical Trial** Shanghai Henlius Biotech Inc. announced that its application to conduct a Phase 1b/2 clinical trial of HLX43 for injection (an anti-PD-L1 antibody-drug conjugate) in combination with HLX07 (a recombinant anti-EGFR humanised monoclonal antibody injection) has been approved by China's National Medical Products Administration. The trial will focus on the treatment of advanced or metastatic solid tumours. Recent results from the phase 1 clinical trial, presented at the 2025 World Conference on Lung Cancer, showed promising efficacy and safety in patients with advanced solid tumours, particularly non-small cell lung cancer. The approval is specific to Shanghai Henlius Biotech Inc., with no indication of grant or funding involvement from other organizations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief on September 30, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10